Direct-Acting Antivirals Still Underused in Hep C-Related Liver Cancer
By Lori Solomon HealthDay Reporter
TUESDAY, Nov. 21, 2023 -- Direct-acting antiviral agents (DAAs) remain underutilized in patients with hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC), according to a study presented at The Liver Meeting, the annual meeting of the American Association for the Study of Liver Diseases, held from Nov. 10 to 14 in Boston.
Leslie Yeeman Kam, M.D., from the Stanford University Medical Center in California, and colleagues assessed the proportion of patients with HCV-related HCC who received DAAs after 2014, as well as factors associated with treatment receipt. The analysis included 3,922 patients with HCV-related HCC identified from Optum's Clinformatics Data Mart Database (2015 to 2021).
The researchers found that 23.5 percent of patients received DAAs. Higher odds of receiving DAA treatment were seen for younger individuals (adjusted hazard ratio [aHR], 0.98), those being seen by a gastroenterologist or infectious disease (with or without oncology) physician (aHR, 3.06), and those with cirrhosis (aHRs, 1.60 and 1.45 for compensated and decompensated, respectively). No differences were seen by sex or race/ethnicity. Five-year survival was significantly higher in DAA-treated patients versus untreated patients (47.2 versus 35.2 percent). The Charlson Comorbidity Index, HCC treatment, and receiving DAA treatment remained significantly associated with lower mortality (aHR, 0.61) when adjusting for age, sex, and race and ethnicity.
"Although those who received DAA treatment had a significantly better five-year survival, DAA treatment remains underutilized even in the sickest of patients with HCV who are insured, as less than one in four patients were treated," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted November 2023
Read this next
USDA Testing Beef for H5N1 Amid Current Outbreak in Dairy Cows
TUESDAY, April 30, 2024 -- On Monday, the U.S. Department of Agriculture announced that it is now testing ground beef for any presence of the H5N1 virus that continues to spread...
Higher Hepatitis C Virus Cure Rates Seen With Facilitated Telemedicine
FRIDAY, April 12, 2024 -- Significantly higher hepatitis C virus cure rates are seen for patients receiving opioid treatment program-integrated facilitated telemedicine versus...
COVID-19 Viral Load Rebound Can Occur After VV116, Nirmatrelvir-Ritonavir
WEDNESDAY, March 20, 2024 -- For patients with mild-to-moderate COVID-19, viral load rebound and symptom rebound can occur after a standard five-day course of treatment with VV116...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.